Squaric acid derivatives with cytotoxic activity-a review

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Squaric acid (SQ) derivatives are a promising class of pharmaceutical agents due to their unique planar aromatic ring, hydrogen bonding capabilities, and reactivity.
• Their structural similarity to carboxylate, phosphate, and amide groups enhances their drug-like properties.

Purpose of the Study:

• This review provides the first comprehensive analysis of squaric acid derivatives' potential applications in anticancer therapies.
• It examines experimental studies published between 2000 and 2024 to assess their efficacy against various cancers.

Main Methods:

• The review analyzes in-vitro studies demonstrating the anticancer activity of squaric acid derivatives.
• It also considers the evaluation of squaric acid derivative-Navarixin in Phase II clinical trials for solid tumors.

Main Results:

• Halogenated squaramides act as ion transporters, disrupting cancer cell ion gradients and inducing apoptosis.
• Squaric acid derivatives are identified as selective inhibitors of enzymes like HDACs, FAK, and kinases involved in tumor progression.
• The cyclobutenedione moiety serves as an effective linker in radiopharmaceuticals for cancer theranostics.

Conclusions:

• Squaric acid derivatives exhibit potent in-vitro anticancer activity, with some compounds showing efficacy in the nanomolar range against diverse cancer cell lines.
• Their multifaceted mechanisms, including ion transport disruption, enzyme inhibition, and theranostic applications, highlight their therapeutic promise.
• Further clinical evaluation, such as Navarixin, is ongoing, underscoring the translational potential of these compounds in oncology.